DG149YZ
Brachytherapy Parathyroid Glands to None with Other Isotope, High Dose Rate (HDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | G Endocrine System |
| Operation | 1 Brachytherapy |
| Body Part | 4 Parathyroid Glands |
| Approach | 9 High Dose Rate (HDR) |
| Device | Y Other Isotope |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for the endocrine system involves placing a radioactive source directly into or immediately next to a gland, such as the thyroid or an adrenal gland, rather than aiming radiation at it from outside the body. Because the source sits so close to the target tissue, it can deliver a concentrated dose to the tumor while limiting exposure to surrounding structures.
This approach is used less often for endocrine tumors than external beam therapy, but it may be chosen when a tumor is well localized and accessible, or when a patient has already received prior external radiation and cannot tolerate additional beam exposure to the area. The radioactive material can be left in place temporarily or permanently, depending on the type of source and the treatment plan developed by the radiation oncology team.
Patients typically undergo a minor procedure to place the source, followed by a defined period during which the radiation is active, after which temporary sources are removed.
Anatomy & Axis Detail
Parathyroid Glands
The parathyroid glands are tiny hormone-producing structures near the thyroid that regulate calcium homeostasis, and interstitial brachytherapy targeting them is rarely performed given their small size and close proximity to vital neck structures. When used, it is typically reserved for recurrent or residual parathyroid carcinoma after surgery, where a sealed radioactive source is placed directly into or near the tumor bed to deliver a concentrated dose that spares the trachea, esophagus, and recurrent laryngeal nerve running nearby. Because the glands can be difficult to visualize precisely and their number varies among individuals, preprocedural localization studies guide source placement, and documentation should note whether the target is a single remaining gland or a broader area of suspected residual disease.
Modality Qualifier: High Dose Rate (HDR)
High Dose Rate (HDR) identifies brachytherapy delivered with a radioactive source of high activity, allowing treatment to be completed in minutes per fraction, often on an outpatient basis with afterloading applicators. It contrasts with Low Dose Rate (LDR), which uses a weaker source left in place for hours to days, trading a longer treatment time for a different radiobiological effect and staffing exposure profile.
Isotope: Other Isotope
Other Isotope is the residual code for a radioactive source used in brachytherapy or systemic radiopharmaceutical therapy that does not correspond to one of the specifically named isotopes in this axis, such as Ir-192, I-125, or Sr-89. It is selected when documentation identifies a distinct radionuclide, or an isotope newly adopted into practice, that lacks its own dedicated value.
Coding & Documentation
The operative note must document direct placement of a radioactive source in or adjacent to the endocrine gland, along with the specific gland treated, to support a code from this family. Coders should confirm whether the source was temporary or permanent, since this can affect qualifier selection and whether a separate removal procedure needs to be captured later. A common mistake is confusing brachytherapy with radioactive iodine ablation for thyroid disease, which is often administered orally or systemically rather than through direct implantation and may not be coded as a procedure in this section at all. Another pitfall is failing to code the placement device or applicator separately when the documentation calls for it under coding guidelines.